IVIM-DWI for Early Therapeutic Effect Assessment of Chemotherapy Combined With Anti-Angiogenic Drugs for Colorectal Cancer Liver Metastases

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054615

Enrollment

Unknown

Registered

2021-12-21

Start date

2017-08-01

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

CapeOX + Bevacizumab Chemotherapy Response Group:None

CapeOX + Bevacizumab Chemotherapy Non-response Group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All patients had pathologically confirmed adenocarcinoma of colon or rectum, with unresectable liver metastases and an expected survival time of greater than 3 months; 2. No prior treatment (including local or systemic therapy) for liver metastases; 3. Presence of at least one measurable lesion (>= 1 cm in diameter) in liver metastases according to RECIST v1.1; 4. ECOG PS score of 0-1; 5. Adequate vital organ reserve.

Exclusion criteria

Exclusion criteria: 1. There are contraindications to MRI examination; 2. Patients with distant metastasis other than liver; 3. Previous history of malignant tumors; 4. Severe cardiovascular diseases; 5. Uncontrolled diabetes, hypertension; 6. Bleeding disorders and unhealed open wounds.

Design outcomes

Primary

Measure	Time frame
perfusion fraction (f);true diffusion coefficient (D);true diffusion coefficient (D);false diffusion coefficient (D);false diffusion coefficient (D);	—

Countries

China

Contacts

Public ContactXin Wang

Zhongshan Hospital Affiliated to Xiamen University

szzj1997@163.com+86 13779960181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026